European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-05-29

Applied venomics of the cone snail species Conus consors for the accelerated, cheaper, safer and more ethical production of innovative biomedical drugs

Objetivo

Venomous animals represent a major source of highly selective and efficient bioactive compounds that have already led to the development of several new drugs. The latest FDA approved example is Prialt, a peptide originating from the venom of a cone snail (Conus magus). CONCO is an innovative post-genomic project dedicated to the discovery and development of novel biopharmaceuticals generated by the broad biodiversity of cone snails.

The project aims at characterizing from the genomic up to potential therapeutic properties all the putative bioactive compounds that can be synthesised by a cone snail species. The genome and transcriptome of Conus consors will be exhaustively studied. Large amounts of venom will be fractionated and submitted to proteomic studies to generate a biochemically characterized 'natural library' of compounds. Large-scale synthesis of each identified candidate will be achieved to form a "synthetic library" of compounds.

Convocatoria de propuestas

FP6-2005-LIFESCIHEALTH-6
Consulte otros proyectos de esta convocatoria

Régimen de financiación

IP - Integrated Project

Coordinador

ATHERIS LABORATORIES, DR RETO STÖCKLIN
Aportación de la UE
Sin datos
Dirección
Chemin d'Alcire 1
PLAN-LES-OUATES - GENEVA
Suiza

Ver en el mapa

Enlaces
Coste total
Sin datos

Participantes (19)